MaxCyte Balance Sheet Health

Financial Health criteria checks 6/6

MaxCyte has a total shareholder equity of $213.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $248.6M and $35.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$153.83m
EquityUS$213.30m
Total liabilitiesUS$35.31m
Total assetsUS$248.61m

Recent financial health updates

Recent updates

Getting In Cheap On MaxCyte, Inc. (LON:MXCT) Might Be Difficult

Dec 10
Getting In Cheap On MaxCyte, Inc. (LON:MXCT) Might Be Difficult

MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 09
MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

May 30
Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10
Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Mar 14
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 07
Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Oct 07
Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Aug 12
Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 15
MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

May 14
Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Apr 27
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Nov 20
Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 02
Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Nov 17
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Jul 25
We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Financial Position Analysis

Short Term Liabilities: MXCT's short term assets ($172.9M) exceed its short term liabilities ($17.6M).

Long Term Liabilities: MXCT's short term assets ($172.9M) exceed its long term liabilities ($17.7M).


Debt to Equity History and Analysis

Debt Level: MXCT is debt free.

Reducing Debt: MXCT has no debt compared to 5 years ago when its debt to equity ratio was 36%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MXCT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MXCT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.3% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:04
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MaxCyte, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Matthew HewittCraig-Hallum Capital Group LLC
Paul CuddonNumis Securities Ltd.